Meeting
2018 ASCO Annual Meeting
Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).
Authors
A. Gomez
Reina Sofia Hospital, University of Cordoba, Maimonides Institute of Biomedical Research, Spanish Cancer Network, Instituto de Salud Carlos III, Cordoba, Spain
A. Gomez , Jose María Vieitez , Silvia Gil , Antonieta Salud Salvia , Begoña Graña Suárez , Pilar Garcia Alfonso , Eva Martínez de Castro , Guillermo Alfonso Quintero Aldana , Juan J Reina , Encarnación González Flores , Mercedes Salgado Fernández , Mercedes Rodríguez Garrote , Ma. José Flor Oncala , Maria Jose Safont , Adelaida La Casta Munoa , Rafael Lopez , Guillot Monica , Beatriz García-Paredes , Eduardo Diaz-Rubio , Enrique Aranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01640405
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3536)
DOI
10.1200/JCO.2018.36.15_suppl.3536
Abstract #
3536
Poster Bd #
29
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
First Author: Meredith Pelster
Poster
2021 Gastrointestinal Cancers Symposium
Olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab: Phase III LYNK-003 study.
First Author: Carlos Alberto Mayo
Poster
2018 ASCO Annual Meeting
Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2017 ASCO Annual Meeting
Cost-effectiveness of front-line trials in metastatic colorectal cancer: Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs..
First Author: Andrea Bonetti